Innovent's arcotatug tavatecan clears OS and PFS in Phase 3 gastric cancer at ESMO

What happened

Innovent Biologics reported that G-HOPE-001, its registrational international Phase 3 trial of arcotatug tavatecan (IBI343), met both primary endpoints: statistically significant and clinically meaningful overall survival and progression-free survival benefits in previously treated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma ^[1]. Innovent presented the result as a Late-Breaking Abstract at the 2026 ESMO Congress ^[1][5]. The trial compared arcotatug tavatecan monotherapy against treatment of investigator's choice ^[2].

Arcotatug tavatecan is a CLDN18.2-directed antibody-drug conjugate that Innovent is developing with Takeda ^[5].

Why it matters

Overall survival is the endpoint regulators and oncologists trust least to subgroup luck and most to real benefit, and a pretreated, biomarker-selected gastric population is a hard place to move it. Earlier in 2026, Innovent said an international Phase 3 in advanced refractory gastric cancer met its primary endpoint and China's NMPA accepted the resulting NDA, which the company billed as "the world's first CLDN18.2 ADC for regulatory review" ^[3]. The G-HOPE-001 readout extends that story from a single-endpoint win to a dual OS-and-PFS result in a defined, testable population ^[1].

For an operator building in CLDN18.2 or in later-line gastric cancer, the signal is that an ADC against this target can carry overall survival, the endpoint that decides a label. That raises the evidentiary bar for any monotherapy or combination still reading out on progression-free survival alone.

What to watch next

• The full ESMO dataset: hazard ratios, medians and p-values for OS and PFS. The late-breaking abstract and presentation are where those numbers land.
• The registry clock. The ClinicalTrials.gov record, last captured on 13 May 2026, listed primary completion as 30 December 2026 and showed the trial active but no longer recruiting ^[2]. That snapshot predates the ESMO announcement and has not been re-pulled to confirm an updated status.
• Regulatory filing timing on the OS data. The dossier carries the earlier China NMPA NDA acceptance ^[3] but no published target action date and no US or EU filing timeline tied to the G-HOPE-001 result.

The now-what

Three moves are on the table for a competing developer:

1. Pressure-test your own CLDN18.2 or gastric-ADC program against an OS comparator rather than a PFS one. If a pivotal design still rests on progression-free survival alone, model how an OS-positive competitor reshapes the label conversation and the commercial ceiling.
2. Wait for the effect sizes before repricing. "Met" with unquantified OS is a directional signal; the hazard ratio decides whether this is a modest shift or a new floor. Hold firm reads until the abstract is in hand.
3. Watch the China-to-global sequencing. Innovent's NMPA filing came first; how and when the OS data converts into filings outside China will set the real competitive timeline.

What Prognyx could not verify

Innovent's release did not include the OS and PFS hazard ratios, medians or p-values, so the magnitude of benefit is not quantifiable from public sources as of this briefing. The dossier does not clarify whether the June 2026 PFS win that supported the China NMPA filing is the same G-HOPE-001 trial maturing to OS or a separate study; the sources do not state this. A Takeda-issued release under its own designation was indexed by a news aggregator that Prognyx could not open to confirm. No US or EU regulatory filing or FDA status for arcotatug tavatecan appears in the public record reviewed here.

Verdict: a credible class-level threat for CLDN18.2 and later-line gastric developers, with the window to act open until the ESMO hazard ratios are public.